BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 10778952)

  • 21. Immunohistochemical detection of p53, mdm2, waf1/p21, and Ki67 proteins in bone marrow biopsies in myelodysplastic syndroms, acute myelogenous leukaemias and chronic myeloproliferative disorders.
    Kanavaros P; Stefanaki K; Rontogianni D; Darivianaki K; Vlychou M; Papadaki E; Eliopoulos G; Bakiri M; Matsouka C; Kakolyris S; Georgoulias V
    Clin Exp Pathol; 1999; 47(5):231-8. PubMed ID: 10598372
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases.
    Blom R; Guerrieri C; Stâl O; Malmström H; Simonsen E
    Gynecol Oncol; 1998 Jan; 68(1):54-61. PubMed ID: 9454661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alterations of cell cycle regulators in localized synovial sarcoma: A multifactorial study with prognostic implications.
    Antonescu CR; Leung DH; Dudas M; Ladanyi M; Brennan M; Woodruff JM; Cordon-Cardo C
    Am J Pathol; 2000 Mar; 156(3):977-83. PubMed ID: 10702413
    [TBL] [Abstract][Full Text] [Related]  

  • 24. p53 and mdm-2 expression in Rhabdomyosarcoma of childhood and adolescence: clinicopathologic study by the Kiel Pediatric Tumor Registry and the German Cooperative Soft Tissue Sarcoma Study.
    Leuschner I; Langhans I; Schmitz R; Harms D; Mattke A; Treuner J;
    Pediatr Dev Pathol; 2003; 6(2):128-36. PubMed ID: 12574910
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of preoperative [18-F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging in patients with resectable soft tissue sarcomas.
    Schwarzbach MH; Hinz U; Dimitrakopoulou-Strauss A; Willeke F; Cardona S; Mechtersheimer G; Lehnert T; Strauss LG; Herfarth C; Büchler MW
    Ann Surg; 2005 Feb; 241(2):286-94. PubMed ID: 15650639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis.
    Eary JF; O'Sullivan F; Powitan Y; Chandhury KR; Vernon C; Bruckner JD; Conrad EU
    Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1149-54. PubMed ID: 12192559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of p53, p21, mdm2, Rb, bax and Ki67 proteins in lymphomas of the mucosa-associated lymphoid (MALT) tissue.
    Stefanaki K; Tzardi M; Kouvidou C; Chaniotis V; Bolioti M; Vlychou M; Zois M; Kakolyris S; Delides G; Rontogianni D; Georgoulias V; Kanavaros P
    Anticancer Res; 1998; 18(4A):2403-8. PubMed ID: 9703886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitative, dynamic 18F-FDG-PET for the evaluation of soft tissue sarcomas: relation to differential diagnosis, tumor grading and prediction of prognosis.
    Okazumi S; Dimitrakopoulou-Strauss A; Schwarzbach MH; Strauss LG
    Hell J Nucl Med; 2009; 12(3):223-8. PubMed ID: 19936332
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
    Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
    Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Fluorine-18]fluorodeoxyglucose positron emission tomography, DNA ploidy and growth fraction in squamous-cell carcinomas of the head and neck.
    Jacob R; Welkoborsky HJ; Mann WJ; Jauch M; Amedee R
    ORL J Otorhinolaryngol Relat Spec; 2001; 63(5):307-13. PubMed ID: 11528276
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [18F]5-fluoro-2-deoxyuridine-PET for imaging of malignant tumors and for measuring tissue proliferation.
    Buchmann I; Vogg AT; Glatting G; Schultheiss S; Möller P; Leithäuser F; Schulte M; Gfrörer W; Kotzerke J; Reske SN
    Cancer Biother Radiopharm; 2003 Jun; 18(3):327-37. PubMed ID: 12954120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of p21WAF1/CIP1 in soft tissue sarcomas: a comparative immunohistochemical study with p53 and Ki-67.
    Pindzola JA; Palazzo JP; Kovatich AJ; Tuma B; Nobel M
    Pathol Res Pract; 1998; 194(10):685-91. PubMed ID: 9820864
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Malignant mixed Müllerian tumors of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 44 cases.
    Blom R; Guerrieri C; Stâl O; Malmström H; Sullivan S; Simonsen E
    Gynecol Oncol; 1998 Jan; 68(1):18-24. PubMed ID: 9454654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic relevance of histologic grading, the cell cycle-associated antigen Ki-S1 and cell cycle regulators in malignant fibrous histiocytomas: a multivariate analysis.
    Brinck U; Cordon-Cardo C; Korabiowska M; Kellner S; Trybus-Galuszka H; Stachura J; Parwaresch MR; Schauer A
    Verh Dtsch Ges Pathol; 1998; 82():232-8. PubMed ID: 10095440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Altered expression of cell cycle regulatory proteins in benign and malignant bone and soft tissue neoplasms.
    Bui MM; Bagui TK; Boulware DC; Letson DG; Nasir A; Kaiser HE; Pledger WJ; Coppola D
    In Vivo; 2007; 21(5):729-37. PubMed ID: 18019405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictive value of proliferation-related markers, p53, and DNA ploidy for survival in patients with soft tissue spindle-cell sarcomas.
    Golouh R; Bracko M; Novak J
    Mod Pathol; 1996 Sep; 9(9):919-24. PubMed ID: 8878024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metabolic activity measured on PET/CT correlates with clinical outcomes in patients with limb and girdle sarcomas.
    Skamene SR; Rakheja R; Dahlstrom KR; Roberge D; Nahal A; Charest M; Turcotte R; Hickeson M; Freeman C
    J Surg Oncol; 2014 Apr; 109(5):410-4. PubMed ID: 24310279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bone and soft-tissue sarcoma: preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging.
    Tateishi U; Yamaguchi U; Seki K; Terauchi T; Arai Y; Kim EE
    Radiology; 2007 Dec; 245(3):839-47. PubMed ID: 18024454
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [(18)F]FMISO and [(18)F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression.
    Rajendran JG; Wilson DC; Conrad EU; Peterson LM; Bruckner JD; Rasey JS; Chin LK; Hofstrand PD; Grierson JR; Eary JF; Krohn KA
    Eur J Nucl Med Mol Imaging; 2003 May; 30(5):695-704. PubMed ID: 12632200
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunoreactivity of p53, Mdm2, p21(WAF1/CIP1) Bcl-2, and Bax in soft tissue sarcomas: correlation with histologic grade.
    Sabah M; Cummins R; Leader M; Kay E
    Appl Immunohistochem Mol Morphol; 2007 Mar; 15(1):64-9. PubMed ID: 17536310
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.